Summary
The effect of impaired liver function on the pharmacokinetics of cimetidine was studied in 8 patients with advanced cirrhosis given single doses of 100 mg i.v. and 400 mg p.o. on separate days. Compared to a control group of 10 healthy volunteers, the total renal and nonrenal clearance was significantly reduced in the cirrhotic patients; (total plasma clearance mean ± SD) 356±181 vs 789±262 ml/min (p<0.01); renal clearance (Clr) 296±100 vs 588±181 ml/min (p<0.01) and nonrenal clearance (Clnr) 97±111 vs 205±89 ml/min (p<0.05). Compared to published results for age-matched ulcer patients, both total and nonrenal clearance were lower whereas renal clearance was within the reported normal range. A significant reduction in volume of distribution (Vdβ) was found, from 2.1±0.1 l/kg in controls to 1.0±0.4l/kg, and in the patient group there was a significant correlation between Vdβ and total plasma clearance (r=0.72, p<0.05). Volume of distribution in steady state (Vdss) did not differ from published results in age-matched controls. No significant change in half-life was found. Bioavailability, estimated by AUC-measurement, showed considerable patient variability (21–143%), with a mean of 70±39%. This was lower than in the controls. In contrast, measurement of urinary excretion showed higher bioavailability in the patients (66±23 vs 51±8%). No correlation was found between any of the kinetic parameters and the clinical and laboratory data. It is suggested that patients with advanced cirrhosis should be closely observed when given cimetidine, and a reduction in dose should be concidered if side effects are to be avoided.
Similar content being viewed by others
References
Bodemar G, Norlander B, Walan A (1981) Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 6: 306–315
Cohen J, Weetman AP, Dargie HJ, Krikler DM (1979) Life-threatening arrythmias and intravenous cimetidine. Br Med J 2: 768
Drayer DE, Romankiewicz J, Lorenzo B and Reidenberg MM (1982) Age and renal clearance of cimetidine. Clin Pharmacol Ther 31: 45–50
Gibaldi M, Koup JR (1981) Pharmacokinetic concepts. Drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol 20: 299–305
Gomeni C, Gomeni R (1978) IGPHARM: Interactive graphic package for pharmacokinetic analysis. Comp Biomed Res 11: 345–361
Grahnén A, von Bahr C, Lindström B, Rosén A (1979) Pharmacokinetics and bioavailability of cimetidine. Eur J Clin Pharmacol 16: 335–340
Gugler R, Brand M, Somogyi A (1981) Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol 20: 225–228
Gugler R, Müller-Liebenau B, Somogyi A (1982) Altered disposition and availability of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol 14: 421–429
Jeffreys DB, Vale J-A (1978) Cimetidine and bradycardia. Lancet 1: 828
Kimelblatt BJ, Cerra FB, Calleri G, Berg MJ, McMillen MA, Schentag JJ (1980) Dose and serum concentration relationship in cimetidine-associated mental confusion. Gastroenterology 78: 791–795
Klinger E, Vaamonde C, Vaamonde L, Lancestremere R, Morosi H, Frisch E, Papper S (1970) Renal function changes in cirrhosis of the liver. Arch Intern Med 125: 1010–1015
Larsson R, Erlanson P, Bodemar G, Walan A, Bertler Å, Franson L, Norlander B (1982) The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 13: 163–170
Mac Mahon B, Bakshi M, Walsh MJ (1981) Cardiac arrythmias after intravenous cimetidine. N Engl J Med 305: 832–833
Narayanan S, Appelton H (1980) Creatinine: a review. Clin Chem 26: 1119–1126
Nouel O, Bernau J, Lebar M, Rueff B, Berhnhamon J-P (1980) Cimetidine-induced mental confusion in patients with cirrhosis. Gastroenterology 79: 606–607
Pancorbo S, Bubrick M, Chin TW, Miller KW, Onstad G (1982) Cimetidine dynamics after single intravenous doses. Clin Pharmacol Ther 31: 83–88
Papper S (1958) The role of the kidney in Laennec's cirrhosis of the liver. Medicine 37: 299–316
Randolph EC, Osborne VL, Walkenstein SS, Intoccia AP (1977) High-pressure liquid chromatographic analysis of cimetidine, a histamin H2-receptor antagonist in blood and urine. J Pharm Sci 66: 1148–1150
Schentag JJ, Cerra FB, Calleri G, De Glopper E, Rose JQ, Bernhard H (1979) Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1: 177–181
Schentag JJ, Cerra FB, Calleri G, Leising M, French M, Bernhard H (1981) Age, disease and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 29: 737–743
Somogyi A, Rohner H-G, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients Clin Pharmacokinet 5: 84–94
Sonne J, Poulsen HE, Døssing M, Larsen NE, Andreasen PB (1981) Cimetidine clearance and bioavailability in hepatic cirrhosis. Clin Pharmacol Ther 29: 191–197
Wagner JC (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4: 443–467
Webster J, Barber HE, Hawksworth GM, Jeffers TA, Petersen J, Petrie JC, Brunt PW, Mowat NAG, Griffiths R (1981) Cimetidine — a clinical and pharmacokinetic study. Br J Clin Pharmacol 11: 333–338
Wilkinson SP, Smith IK, Clarke M, Arroudo V, Richardson J, Moodie H, Williams R (1979) Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci 56: 169–177
Author information
Authors and Affiliations
Additional information
Part of this study has been reported as a “Letter to the Editor”, N Engl J Med (1982): 307, 187
Rights and permissions
About this article
Cite this article
Grahnén, A., Jameson, S., Lööf, L. et al. Pharmacokinetics of cimetidine in advanced cirrhosis. Eur J Clin Pharmacol 26, 347–355 (1984). https://doi.org/10.1007/BF00548766
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00548766